Novartis' Cosentyx Gives More Additional Benefit Than Stelara, Says German HTA
This article was originally published in Scrip
Novartis AG's Cosentyx (secukinumab) offers some plaque psoriasis patients "considerable additional benefit" over Johnson & Johnson's Stelara (ustekinumab), says the G-BA, the body in charge of Germany's AMNOG benefit assessment and pricing process. The news means that Novartis should find it easier to argue a better price during negotiations with health insurers.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.